Clinuvel Pharmaceuticals Limited
CLVLF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $95 | $88 | $78 | $66 |
| % Growth | 7.8% | 12.6% | 19.2% | – |
| Cost of Goods Sold | $16 | $8 | $9 | $10 |
| Gross Profit | $79 | $80 | $70 | $55 |
| % Margin | 83.3% | 91.2% | 88.8% | 84% |
| R&D Expenses | $0 | $0 | $1 | $1 |
| G&A Expenses | $27 | $25 | $23 | $18 |
| SG&A Expenses | $27 | $25 | $23 | $18 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $7 | $6 | $2 | $1 |
| Operating Expenses | $33 | $31 | $25 | $20 |
| Operating Income | $46 | $48 | $45 | $36 |
| % Margin | 48.1% | 54.4% | 57.3% | 54.9% |
| Other Income/Exp. Net | $6 | $2 | $1 | -$2 |
| Pre-Tax Income | $52 | $51 | $46 | $34 |
| Tax Expense | $15 | $15 | $15 | $13 |
| Net Income | $36 | $36 | $31 | $21 |
| % Margin | 38.1% | 40.4% | 39.1% | 31.8% |
| EPS | 0.72 | 0.72 | 0.62 | 0.42 |
| % Growth | 0% | 16.1% | 47.6% | – |
| EPS Diluted | 0.72 | 0.7 | 0.59 | 0.4 |
| Weighted Avg Shares Out | 50 | 50 | 49 | 49 |
| Weighted Avg Shares Out Dil | 50 | 51 | 52 | 52 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $7 | $4 | $0 |
| Interest Expense | $4 | $4 | $3 | $2 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $57 | $56 | $50 | $37 |
| % Margin | 60.2% | 63.8% | 63.3% | 56.8% |